DXS INTERNATIONAL PLC
Notification of Director / PDMR Dealing
The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification that on 10 December 2020 Mr Bob Sutcliffe, the Chairman, purchased 13,333 Ordinary Shares in the Company at a price of 7.5p per share.
Following the transaction specified above Mr Sutcliffe has a beneficial holding of 545,382 Ordinary Shares representing 1.30% of the issued share capital of the Company.
| 1
|
Details of the person discharging managerial responsibilities / person closely associated | ||||
| a)
|
Name
|
Robert Sutcliffe
|
|||
| 2 | Reason for the notification | ||||
| a)
|
Position/status
|
Chairman | |||
| b)
|
Initial notification /Amendment
|
Initial | |||
| 3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
| a)
|
Name
|
DXS INTERNATIONAL PLC | |||
| b)
|
LEI
|
2138001R1KEUWTXEVJ44 | |||
| 4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a)
|
Description of the financial instrument, type of instrument | Ordinary Shares of 0.33p each | |||
| Identification code | ISIN GB00B2Q6HZ92 | ||||
| b)
|
Nature of the transaction
|
Purchase | |||
| c)
|
Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 7.5p | 13,333 | ||||
| d)
|
Aggregated information | ||||
| – Aggregated volume | |||||
| – Price | |||||
| e)
|
Date of the transaction
|
10 December 2020 | |||
| f)
|
Place of the transaction
|
AQSE | |||
The Directors of DXS International plc accept responsibility for this announcement
Enquiries:
| David Immelman (Chief Executive) DXS International plc |
01252 719800 david@dxs-systems.com |
| Wrecclesham House Wrecclesham Road Farnham Surrey GU10 4PS |
|
| www.dxs-systems.co.uk |
| Corporate Advisor
|
|
| David Papworth City & Merchant |
0207 101 7676
|
| Corporate Broker
|
|
| Hybridan LLP Claire Louise Noyce
|
020 3764 2341
|
Note to Editors:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq:…
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed”…
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined…
HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2024 December 27, 2024, 6.00 p.m. Safe Group announces…
GRANTS, NEW MEXICO, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright…
BOSTON, Dec. 27, 2024 /PRNewswire/ -- Judge Baker Children's Center d/b/a The Baker Center for…